35 294

Cited 31 times in

Low expression of Bax predicts poor prognosis in patients with locally advanced esophageal cancer treated with definitive chemoradiotherapy.

Authors
Kang, SY; Han, JH; Lee, KJ; Choi, JH; Park, JI; Kim, HI; Lee, HW; Jang, JH; Park, JS; Kim, HC; Kang, S; Oh, YT; Chun, M; Kim, JH; Sheen, SS; Lim, HY
Citation
Clinical cancer research : an official journal of the American Association for Cancer Research, 13(14):4146-4153, 2007
Journal Title
Clinical cancer research : an official journal of the American Association for Cancer Research
ISSN
1078-0432
Abstract
PURPOSE: The present study evaluated the prognostic significance of apoptosis-related proteins, p53, Bcl-2, Bax, and galectin-3 in patients with locally advanced esophageal cancer treated with definitive chemoradiotherapy.



EXPERIMENTAL DESIGN: A total of 63 patients with locally advanced esophageal cancer (squamous cell carcinoma: 62; adenocarcinoma: 1; stages II-IV) were treated with definitive chemoradiotherapy using 5-fluorouracil and cisplatin combined with radiotherapy. Pretreatment tumor biopsy specimens were analyzed for p53, Bcl-2, Bax, and galectin-3 expression by immunohistochemistry.



RESULTS: High expression of Bax, p53, Bcl-2, and galectin-3 was observed in 67%, 47%, 24%, and 29% of patients, respectively. The median overall survival (OS) of total patients was 14 months with 16% of 3-year OS. High expression of p53, Bcl-2, and galectin-3 did not show correlation with clinicopathologic characteristics, including patient outcome. Low expression of Bax was significantly correlated with lack of clinical complete response (P=0.023). Low expression of Bax was also associated with poor OS (median, 8 months versus 16 months; P=0.0008) in univariate analysis. In multivariate analysis, low expression of Bax was the most significant independent predictor of poor OS (P=0.009), followed by low dose intensity of cisplatin and lack of clinical complete response.



CONCLUSIONS: Low expression of Bax was significantly associated with the poor survival of patients with locally advanced esophageal cancer treated with chemoradiotherapy using 5-fluorouracil and cisplatin. Immunohistochemical staining for Bax with a pretreatment biopsy specimen might be useful to select the optimal treatment options for these patients.
MeSH terms
AdultAgedAged, 80 and overAntineoplastic Agents/therapeutic useApoptosisCombined Modality TherapyEsophageal Neoplasms/genetics*Esophageal Neoplasms/mortalityEsophageal Neoplasms/pathologyEsophageal Neoplasms/therapyGene Expression Regulation, Neoplastic*HumansMiddle AgedNeoplasm Proteins/analysisNeoplasm StagingPrognosisRadiotherapy/methodsRetrospective StudiesSurvival Analysisbcl-2-Associated X Protein/genetics*
DOI
10.1158/1078-0432.CCR-06-3063
PMID
17634542
Appears in Collections:
Journal Papers > School of Medicine / Graduate School of Medicine > Hematology-Oncology
Journal Papers > School of Medicine / Graduate School of Medicine > Pathology
Journal Papers > School of Medicine / Graduate School of Medicine > Gastroenterology
Journal Papers > School of Medicine / Graduate School of Medicine > Radiation Oncology
Journal Papers > School of Medicine / Graduate School of Medicine > Pulmonary & Critical Care Medicine
AJOU Authors
강, 석윤한, 재호이, 광재최, 진혁이, 현우박, 준성김, 효철강, 승희오, 영택전, 미선김, 장희신, 승수
Full Text Link
Export
RIS (EndNote)
XLS (Excel)
XML

qrcode

해당 아이템을 이메일로 공유하기 원하시면 인증을 거치시기 바랍니다.

Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.

Browse